DOYLESTOWN, Pa. , March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that an

DOYLESTOWN, Pa. , March 07, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren

DOYLESTOWN, Pa. , March 01, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it

DOYLESTOWN, Pa. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the closing

DOYLESTOWN, Pa. , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the pricing

DOYLESTOWN, Pa. , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced it has

DOYLESTOWN, Pa. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received an award notification

DOYLESTOWN, Pa. , Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced a one-for-twenty reverse

DOYLESTOWN, Pa. , Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Chief

DOYLESTOWN, Pa. , Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6 th